Trusted Resource for Clinical Trials, Protocols & Progress
In recent years, biomarkers have become integral to clinical development, serving critical roles in patient stratification, endpoint analysis, and therapeutic monitoring. However, due to their often unstable nature, proper storage of biomarker samples has emerged as a major focus area for global regulatory authorities.
Click to read the full article.
In global clinical trials, sponsors often engage both central laboratories and local site-based laboratories for sample analysis. While central labs offer consistency and validated methods, local labs may be used for logistical convenience, urgent testing, or regulatory requirements. This dual-lab setup introduces challenges in method comparability, data reliability, and regulatory compliance.
Click to read the full article.
In long-duration or multi-phase clinical trials, sponsors may find it necessary to change or upgrade the bioanalytical method used to analyze biological samples. These changes may be driven by improved assay sensitivity, revised biomarker panels, lab transitions, or regulatory updates. However, such transitions raise critical questions about data continuity and comparability.
Click to read the full article.
Bioanalytical laboratories supporting clinical trials routinely encounter scenarios where test results may be flagged for potential re-analysis. These may include unexpected values, assay drift, out-of-specification (OOS) results, or stability-related deviations. Re-analysis refers to repeating the sample test using the same validated method to confirm or clarify the original result.
Click to read the full article.
Bioanalytical sample integrity is vital to the success of clinical trials, particularly when evaluating pharmacokinetics, drug efficacy, or biomarker data. Analyte instability—defined as the degradation or transformation of a substance within a stored biological matrix—can compromise data validity and trigger regulatory scrutiny.
Click to read the full article.
In regulated clinical trials, bioanalytical samples must be stored under validated and documented conditions to preserve analyte integrity. Long-term storage failures—whether due to temperature excursions, equipment malfunction, or procedural errors—can jeopardize data integrity and lead to regulatory observations. These failures often go unnoticed until re-analysis, regulatory inspection, or sample shipment triggers a deviation report.
Click to read the full article.
Central laboratories have become an essential part of global clinical trial infrastructure. Their appeal lies in their ability to provide standardized testing, centralized data processing, and streamlined communication between sponsors, CROs, and investigators. Central lab standardization can mitigate variability across sites, support protocol adherence, and improve regulatory compliance. However, centralization also brings its own set of challenges—especially when regulatory audits assess consistency, data traceability, and SOP alignment.
Click to read the full article.
Turnaround time (TAT) for laboratory test results plays a significant role in maintaining trial timelines, ensuring subject safety, and meeting regulatory expectations. Whether dealing with pharmacokinetic endpoints, safety labs, or biomarker readouts, delays in lab data can compromise protocol compliance and data integrity. FDA and EMA inspections frequently highlight TAT discrepancies as audit findings, especially in trials involving multiple sites with varied lab models.
Click to read the full article.
Local laboratories play an important role in expediting clinical trial operations, especially in decentralized or rural research settings. However, they often lack the comprehensive test menus, harmonized methodologies, and qualification processes offered by central labs. This leads to inconsistent data, challenges in comparing results across sites, and significant inspection findings.
Click to read the full article.
Central laboratories offer standardized testing, improved data integrity, and harmonized methods in global clinical trials. However, the logistics of safely and compliantly shipping biological samples from collection sites to these labs remains a complex, risk-prone task. Improper handling, temperature excursions, or delayed shipments can lead to sample degradation and data loss.
Click to read the full article.
